B
OPNT

Bailard’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Bailard’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,042
Closed -$322K – 838
2022
Q1 		$322K Sell
15,042
-1,200
-7% -$31.8K 0.01% 508
2021
Q4 		$546K Hold
16,242
– – 0.02% 392
2021
Q3 		$418K Buy
+16,242
New +$290K 0.01% 438

Other funds holding OPNT

HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bailard's OPNT Position: Q2 2022 in Review

Bailard sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q2 2022, closing a stake of 15,042 shares — an estimated $322K sold.

Bailard first reported a position in OPNT in Q3 2021 and held it in 3 quarters. The position peaked at $546K in Q4 2021. 33 funds tracked by Wall St. Rank hold OPNT as of Q2 2022.

  • Bailard reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bailard sold 15,042 Opiant Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $322K.
  • Bailard first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Bailard's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $546K in Q4 2021.
  • 33 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Bailard's 13F filing for Q2 2022, filed 27 Jul 2022.